Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | ACR | P10323 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10075826 | 0.88 | L3MBTL1 (0.39) | L3MBTL1MAPTGAARAB9ATSHR | |
| SCHEMBL10075801 | 0.85 | L3MBTL1 (0.35) | L3MBTL1MAPTGAATSHR | |
| SCHEMBL20709713 | 0.84 | L3MBTL1 (0.38) | L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10075730 | 0.83 | L3MBTL1 (0.42) | L3MBTL1MAPTFAAHGAARAB9A | |
| SCHEMBL31098997 | 0.83 | POLB (0.48) | L3MBTL1MAPTGAARAB9ASMN1; SMN2 | |
| SCHEMBL10075831 | 0.83 | THRA (0.44) | L3MBTL1MAPTGAASMN1; SMN2RARB | |
| SCHEMBL10075727 | 0.82 | GAA (0.43) | L3MBTL1MAPTGAATSHRSMN1; SMN2 | |
| SCHEMBL20783443 | 0.82 | GAA (0.43) | L3MBTL1MAPTGAATSHRSMN1; SMN2 | |
| SCHEMBL22639048 | 0.82 | GAA (0.43) | L3MBTL1MAPTGAATSHRSMN1; SMN2 | |
| SCHEMBL21870374 | 0.81 | L3MBTL1 (0.39) | L3MBTL1MAPTGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2586827-B1 | CURABLE RESIN COMPOSITION | ADEKA CORP (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-8735511-B2 | Curing resin composition | ADEKA CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8735511-B2 | Curing resin composition | ADEKA CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2586827-A1 | CURABLE RESIN COMPOSITION | Adeka Corporation (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-20120115972-A1 | CURING RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115972-A1 | CURING RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8148045-B2 | Oxime ester compound and photopolymerization initiator containing the same | ADEKA CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148045-B2 | Oxime ester compound and photopolymerization initiator containing the same | ADEKA CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-2327689-B1 | Oxime ester compound and photopolymerization initiator containing the same | ADEKA CORP (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20110129778-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME | ADEKA CORPORATION (JP) | 2011-06-02 | — | — | US | disclosed |
| US-20110129778-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME | ADEKA CORPORATION (JP) | 2011-06-02 | — | — | US | disclosed |
| EP-2327689-A1 | Oxime ester compound and photopolymerization initiator containing the same | Adeka Corporation (JP) | 2011-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129778-A1 | OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME | OXER1, OR10J3, CDK11B | L3MBTL1 1628/4885MAPT 3494/4885MMP1 4291/4885 |
| US-20120115972-A1 | CURING RESIN COMPOSITION | LTA, LOXL1, PLOD2 | L3MBTL1 228/4885MAPT 154/4885MMP1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.